Phase II clinical trial - Sein métastatique HER2+

HER2CLIMB (ONT-380-206)
Sein métastatique HER2+
Essai clinique fermé
Public cible
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)
Description de l'essai
The purpose of this study is to assess the effect of tucatinib vs. placebo in combination with capecitabine and trastuzumab on progression-free survival (PFS) per RECIST 1.1 based on independent central review.
Investigateur principal